Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16M | -11M | -7M | -6M | -599K |
| EBITDA | -16M | -17M | -7M | -6M | -599K |
| Net Income | -18M | -15M | -13M | -8M | -599K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0005
-28.57% today
1Y Change
+600.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PaxMedica, Inc. Common Stock (PXMD) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 600.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +61.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +61.7%, free cash flow -77.4% with operating margin 0.0% and ROIC -415.6%. Stock Foundry combines PXMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PXMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PXMD Max Drawdown
-98.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PXMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$599.0K
+92.9% YoY
Free Cash Flow
-$419.4K
+82.1% YoY
Revenue Growth
+0.0%
EPS Growth
+61.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16M | -11M | -7M | -6M | -599K |
| EBITDA | -16M | -17M | -7M | -6M | -599K |
| Net Income | -18M | -15M | -13M | -8M | -599K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 2M | 444K | 1M | 25K |
| Total Assets | 6M | 2M | 649K | 1M | 25K |
| Total Liabilities | 2M | 2M | 11M | 6M | 123K |
| Shareholder Equity | 3M | 109K | -10M | -5M | -98K |
| Total Debt | 0 | 174K | 0 | 612K | 0 |
| Net Debt | -5M | -2M | -444K | -512K | -25K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
419K
+82.1% YoY
Capital Expenditures
0
Free Cash Flow
419K
+82.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1047.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.